Saudi Pharmaceutical Industries and Medical Appliances Corp

Last Updated:
  • 34.30 SAR
  • -0.15
  • -0.44%
الشركة السعودية للصناعات الدوائية والمستلزمات الطبية
الدوائية
Symbol : 2070
ISIN : SA0007879188
52-Week Range : 27.45 - 45.25
Turnover Ratio : 1.45
Market : Saudi Exchange
Sector : Pharma, Biotech & Life Science
Industry : Pharmaceuticals and Biotechnology Research & Development
Sub-Industry :

Basic Information

  • Activity :
    Saudi Pharmaceutical Industries and Medical Appliances Corp (known as: SPIMACO) is a public company, listed on Saudi Stock Exchange “Tadawul” (TDWL) since October 1993. SPIMACO operates within the Pharmaceuticals,...
  • Industry Group :
    pharmaceuticals Research and Biotechnology
  • Sub-Industry :
  • ISIN :
    SA0007879188
  • Contact Person :
  • Established On:
    20-Jan-1986
  • Stock Listing On :
    31-Oct-1993
  • No of Employees :
    1,200 Employees as of 2018
  • Outstanding Shares :
    120,000,000
  • Free Float Shares :
  • Par Value :
  • Paid Capital :
  • Market Cap :
  • Authorized Capital :

Indices Membership

Action Date Index Provider
Join 2017 Pharma, Biotech & Life Science Saudi Exchange Co
Leave 2017 Industrial Investment Saudi Exchange Co
Join 1993 Industrial Investment Saudi Exchange Co
Join 1993 Tadawul All Share Index (TASI) Saudi Exchange Co
Saudi Pharmaceutical Industries and Medical Appliances Corp
Prince Salman Bin Muhammed Bin Saud street - AS SAHAFAH P.O.Box 20001 Riyadh 11455, Kingdom of Saudi Arabia
T : +966 11 2523320
F : +966 11 2523300
www.spimaco.com.sa
investor.relations@spimaco.sa

Management

Title Name As Of
Chairman: Ahmed Aljedai 2023
CEO: Jerome Cabannes 2023
Deputy Chairman: Ammar Al Khudairy 2019
Board Member: Khalid Al Gwaiz 2019
Abdulrahman Al Thinyan 2022
Faisal Shaker 2019
Fahad Al Rabiah 2022
Mai AlAjaji 2022
Mohammad Mohammad
Adill Ahmed

Reports

Date Title File
2024 SPIMACO Announces SAR 40 million net income in 1Q 2024
2024 SPIMACO Annual Financials Report 2023
2024 SPIMACO Maintains Top Position in Private Sector with Consistent Revenue Growth in FY 2023
2024 SPIMACO Confirms Jerome Cabannes as CEO
2024 SPIMACO Forges Strategic Alliance with Recbio for Recombinant HPV-9 Vaccine
2023 SPIMACO to Acquire Osmopharm, a Swiss Pharmaceutical Drug Delivery Innovator
2023 SPIMACO Quarterly Financials Report Q3 2023
2023 SPIMACO Quarterly Financials Report Q2 2023
2023 SPIMACO announces SAR 79 million net income in 1H 2023 and raises FY 2023 guidance
2023 SPIMACO Quarterly Financials Report Q1 2023
2023 SPIMACO Announces 85% year-on-year net income growth to SAR 57 million in 1Q 2023
Check our coverage for